Repare Therapeutics Inc. shareholders have approved the acquisition by XenoTherapeutics, Inc.
The approval was received at a special meeting of shareholders held on January 16, 2026
The acquisition involves all issued and outstanding common shares of Repare Therapeutics Inc.
Approval of Acquisition
Shareholders approved the acquisition by 99.76% of the votes cast at the meeting.
Compensation Approval
Compensation for named executive officers related to the arrangement was approved on an advisory basis by 99.34% of shareholder votes.
Voluntary Liquidation
In the event of termination, shareholders voted overwhelmingly for the voluntary liquidation and dissolution of the Company.
Court Approval Pending
The final order to approve the arrangement is expected to be sought from the Superior Court of Qu\u00e9bec on January 23, 2026.
- The acquisition approval signifies a major decision by Repare Therapeutics Inc. shareholders.
- The voluntary liquidation approval indicates the willingness of shareholders to proceed with dissolution if needed.
The approval of the acquisition by shareholders and the subsequent steps outlined in the filing set the stage for the completion of the transaction by January 28, 2026.